Veru Inc. has released a presentation detailing its ongoing focus on cardiometabolic diseases, highlighting advancements in its drug candidate pipeline. The company is developing a combination therapy of Enobosarm, an oral selective androgen receptor modulator (SARM), and a GLP-1 receptor agonist aimed at improving weight loss outcomes while preserving muscle mass and function in patients undergoing GLP-1-based weight reduction therapy. The Phase 2 QUALITY Study for this program has been completed, with a Phase 2b PLATEAU study scheduled to begin patient enrollment in early 2026. The presentation notes a significant increase in GLP-1 receptor agonist use among American adults, with approximately 43 million users in 2025, up from 20 million in 2024. It also addresses challenges associated with GLP-1 therapies, including the nonselective loss of both muscle and fat, and the high incidence of patients reaching a weight loss plateau. Veru is also advancing Sabizabulin, an oral microtubule disruptor with anti-inflammatory properties, for the potential treatment of atherosclerosis in patients with stable coronary artery disease, with a Phase 2 trial planned. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief on November 19, 2025, and is solely responsible for the information contained therein.
Comments